UroGen Pharma (URGN) Net Income towards Common Stockholders (2017 - 2026)
UroGen Pharma (URGN) posted Net Income towards Common Stockholders of -$23.6 million for Q1 2026, up 10.91% on a QoQ basis from -$26.5 million in Q4 2025, and up 46.23% year-over-year from -$16.1 million in Q1 2025.
UroGen Pharma (URGN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
UroGen Pharma's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$23.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 46.23% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.3 million (down 24.52% YoY) and the FY2025 annual result came in at -$153.6 million, down 60.81% from the prior year.
- Net Income towards Common Stockholders was -$23.6 million for Q1 2026 at UroGen Pharma, up from -$26.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$6.1 million in Q4 2024 and bottomed at -$49.9 million in Q2 2025.
- A 5-year average of -$28.6 million and a median of -$27.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 1462.18% — and 2024, when it surged 77.88%.
- UroGen Pharma's Net Income towards Common Stockholders stood at -$28.9 million in 2022, then increased by 3.7% to -$27.8 million in 2023, then jumped by 77.88% to -$6.1 million in 2024, then sank by 330.26% to -$26.5 million in 2025, then gained by 10.91% to -$23.6 million in 2026.
- Business Quant data shows URGN's Net Income towards Common Stockholders at -$23.6 million in Q1 2026, -$26.5 million in Q4 2025, and -$33.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn | -23.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.57 Mn |
| Dec 31, 2025 | -26.46 Mn |
| Sep 30, 2025 | -33.35 Mn |
| Jun 30, 2025 | -49.94 Mn |
| Mar 31, 2025 | -43.84 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -23.67 Mn |
| Jun 30, 2024 | -33.40 Mn |
| Mar 31, 2024 | -32.29 Mn |
| Dec 31, 2023 | -27.80 Mn |
| Sep 30, 2023 | -21.88 Mn |
| Jun 30, 2023 | -24.14 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -28.87 Mn |
| Sep 30, 2022 | -25.83 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -28.39 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -30.21 Mn |
| Jun 30, 2021 | -26.22 Mn |